- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02842866
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults Age 56 Years and Older
The aim of the study was to demonstrate non-inferiority of immunogenicity and evaluate the safety of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid conjugate vaccine (MenACYW conjugate vaccine) compared to a single dose of Meningococcal Polysaccharide Vaccine Serogroups A, C, Y, and W-135 Combined (Menomune® - A/C/Y/W-135) in adults 56 years of age and older in the United States.
Primary objective:
-To demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW conjugate vaccine compared to those observed following the administration of a single dose of Menomune® - A/C/Y/W-135.
Secondary objective:
-To compare the serum bactericidal assay using human complement (hSBA) antibody geometric mean titers of meningococcal serogroups A, C, Y, and W following the administration of MenACYW conjugate vaccine to those observed following the administration of Menomune® - A/C/Y/W-135.
Observational objectives:
- To describe antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA at baseline (before vaccination) and 30 days after vaccination with MenACYW conjugate vaccine or Menomune® - A/C/Y/W-135 in a subset of 100 participants per treatment group.
- To describe the safety profile of MenACYW conjugate vaccine compared to that of the licensed Menomune® - A/C/Y/W-135 after a single administration.
Study Overview
Status
Detailed Description
Participants were randomized in a 1:1 ratio to receive a single dose of MenACYW conjugate vaccine or Menomune® - A/C/Y/W-135 on Day 0 (Visit 1).
Participants underwent immunogenicity assessment at baseline (pre-vaccination) and at 30 to 44 days post-vaccination and were also evaluated for safety up to Day 180 post-vaccination.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00918
-
-
-
-
Arizona
-
Chandler, Arizona, United States, 85224
-
-
California
-
Anaheim, California, United States, 92801
-
San Diego, California, United States, 92103
-
-
Connecticut
-
Waterbury, Connecticut, United States, 06708
-
-
Florida
-
Clearwater, Florida, United States, 33756
-
DeLand, Florida, United States, 32720
-
Jacksonville, Florida, United States, 32205
-
Jacksonville, Florida, United States, 32216
-
Ponte Vedra, Florida, United States, 32081
-
Port Orange, Florida, United States, 32127
-
West Palm Beach, Florida, United States, 33409
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
-
Newton, Kansas, United States, 67114
-
Wichita, Kansas, United States, 67205
-
-
Maryland
-
Elkridge, Maryland, United States, 21075
-
-
Massachusetts
-
Quincy, Massachusetts, United States, 02169
-
-
Michigan
-
Troy, Michigan, United States, 48098
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
-
-
New York
-
Endwell, New York, United States, 13760
-
-
North Carolina
-
Greensboro, North Carolina, United States, 27408
-
Raleigh, North Carolina, United States, 27612
-
Winston-Salem, North Carolina, United States, 27103
-
-
North Dakota
-
Fargo, North Dakota, United States, 58104
-
-
Ohio
-
Cincinnati, Ohio, United States, 45236
-
Cincinnati, Ohio, United States, 45246
-
-
Oregon
-
Grants Pass, Oregon, United States, 97527
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18012
-
Uniontown, Pennsylvania, United States, 15401
-
-
South Carolina
-
Mount Pleasant, South Carolina, United States, 29464
-
Mount Pleasant, South Carolina, United States, 29646
-
-
Texas
-
Dallas, Texas, United States, 75231
-
Dallas, Texas, United States, 75234
-
-
Utah
-
South Jordan, Utah, United States, 84095
-
West Jordan, Utah, United States, 84088
-
-
Virginia
-
Charlottesville, Virginia, United States, 22911
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged ≥56 years on the day of inclusion.
- Informed consent form had been signed and dated.
- Attended all scheduled visits and complied with all trial procedures.
Exclusion Criteria:
- Participant was pregnant, or lactating, or of childbearing potential (were considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination).
- Participation in the 4 weeks preceding the trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
- Receipt of any vaccine in the 4 weeks (28 days) preceded the trial vaccination or planned receipt of any vaccine prior to Visit 2 except for influenza vaccination, which might be received at least 2 weeks before or after study vaccine. This exception included monovalent pandemic influenza vaccines and multivalent influenza vaccines.
- Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroups A, C, Y, or W; or meningococcal B vaccine).
- Receipt of immune globulins, blood or blood-derived products in the past 3 months.
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
- History of meningococcal infection, confirmed either clinically, serologically, or microbiologically.
- At high risk for meningococcal infection during the trial (specifically, but not limited to, participants with persistent complement deficiency, with anatomic or functional asplenia, or participants travelling to countries with high endemic or epidemic disease).
- Known systemic hypersensitivity to latex or any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances.
- Personal history of Guillain-Barré syndrome.
- Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine within at least 10 years of the proposed study vaccination.
- Verbal report of thrombocytopenia, contraindicating IM vaccination, in the Investigator's opinion.
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination in the Investigator's opinion.
- Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
- Current alcohol abuse or drug addiction.
- Chronic illness that, in the opinion of the investigator, was at a stage where it might interfere with trial conduct or completion.
- Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature >=100.4 degree [°] Fahrenheit [F]). A prospective participant was not included in the study until the condition had resolved or the febrile event had subsided.
- Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
- Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1: MenACYW Conjugate Vaccine
Healthy, adult participants aged greater than or equal to (≥) 56 years received a single dose of MenACYW Conjugate Vaccine on Day 0.
|
0.5 milliliter (mL), Intramuscular (IM), single dose on Day 0.
Other Names:
|
Active Comparator: Group 2: Menomune® Vaccine
Healthy, adult participants aged ≥56 years received a single dose of Menomune®- A/C/Y/W-135 Vaccine on Day 0.
|
0.5 mL, Subcutaneous (SC), single dose on Day 0.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menomune® Vaccine
Time Frame: Day 30 (Post-vaccination)
|
Vaccine seroresponse for serogroups A, C, Y, and W was measured by serum bactericidal assay using human complement (hSBA).
It was defined as post-vaccination hSBA titers ≥1:16 for participants with pre-vaccination hSBA titers less than (<) 1:8, or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers ≥1:8.
|
Day 30 (Post-vaccination)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine or Menomune® Vaccine
Time Frame: Day 30 (Post-vaccination)
|
GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA method.
|
Day 30 (Post-vaccination)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Infections
- Central Nervous System Infections
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Meningitis, Bacterial
- Central Nervous System Bacterial Infections
- Neisseriaceae Infections
- Meningitis, Meningococcal
- Meningitis
- Meningococcal Infections
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- MET49
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meningitis
-
Prof. Elizabeth MillerNovartis VaccinesCompletedMeningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup WUnited Kingdom
-
University Hospital, Strasbourg, FranceCompleted
-
Assiut UniversityUnknown
-
University Medical Centre LjubljanaHarvard University; University of Ljubljana School of Medicine, Slovenia; Slovenian...Unknown
-
University of MinnesotaNational Institute of Neurological Disorders and Stroke (NINDS); Medical Research... and other collaboratorsCompletedCryptococcal Meningitis | Fungal MeningitisUganda
-
Rambam Health Care CampusWithdrawnGram Negative Meningitis | Post Traumatic Bacterial MeningitisIsrael
-
Charite University, Berlin, GermanyRecruitingBacterial Meningitis | Implant Infection | Fungal MeningitisGermany
-
Brigham and Women's HospitalActive, not recruitingPreventive Immunization; MeningitisUnited States
-
Matinas BioPharma Nanotechnologies, Inc.University of MinnesotaNot yet recruitingCryptococcal Meningitis
Clinical Trials on Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisUnited States, Puerto Rico
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisFinland, Germany, Hungary, Spain
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisFinland
-
SanofiCompletedMeningococcal Immunisation (Healthy Volunteers)Japan
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningococcal Immunisation (Healthy Volunteers)Denmark, Finland, Germany
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisUnited States, Puerto Rico
-
Sanofi Pasteur, a Sanofi CompanyRecruiting
-
Sanofi Pasteur, a Sanofi CompanyCompletedHealthy Volunteers (Meningococcal Infection)India, South Africa
-
Sanofi Pasteur, a Sanofi CompanyCompletedHealthy Volunteers (Meningococcal Infection)Lebanon, Turkey